We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04731818
Previous Study | Return to List | Next Study

An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04731818
Recruitment Status : Completed
First Posted : February 1, 2021
Last Update Posted : June 16, 2022
Eastern Virginia Medical School (EVMS)
Information provided by (Responsible Party):
ZabBio Inc.

Brief Summary:
This is an early Phase 1 study to establish proof-of-concept by determining whether an intravaginal film containing a human contraceptive antibody (ZB-06) shows promise to provide contraceptive efficacy using the post-coital test, a surrogate measure of efficacy. The study will also evaluate the safety and pharmacokinetics of ZB-06.

Condition or disease Intervention/treatment Phase
Contraception Biological: ZB-06 Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is a Phase 1a, single center, open-label, crossover, mechanism of action and proof of concept study.
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: An Exploratory Phase 1 Mechanism-of-action Study of ZB-06, a Vaginal Film Containing HC4-N, an Anti-sperm Monoclonal Antibody.
Actual Study Start Date : January 27, 2021
Actual Primary Completion Date : February 24, 2022
Actual Study Completion Date : April 27, 2022

Arm Intervention/treatment
Experimental: ZB-06
All participants will receive a single ZB-06 film for intravaginal administration prior to intercourse.
Biological: ZB-06
ZB-06 is a polyvinyl alcohol-based film containing 20 mg of human contraceptive antibody (HCA) for topical intravaginal administration.

Primary Outcome Measures :
  1. Surrogate Contraceptive Efficacy [ Time Frame: 2-3 hours after sexual intercourse. ]
    Number of progressively motile sperm in aspirated endocervical mucus when using ZB-06 prior to intercourse.

Secondary Outcome Measures :
  1. Safety [ Time Frame: Baseline through study exit encompassing a minimum of three menstrual cycles of 21-35 days. ]
    Incidence of adverse events during product use versus during baseline observation.

Other Outcome Measures:
  1. Pharmacokinetics [ Time Frame: Baseline, 2-3 hours & 24 hours & 1-month post-intercourse, with and without product use. ]
    Concentration of ZB-06 human contraceptive antibody in vaginal fluid, endocervical mucus, and serum.

  2. Pharmacokinetics [ Time Frame: Baseline, 2-3 hours & 24 hours & 1-month post-intercourse, with and without product use. ]
    Sperm agglutination titer of ZB-06 human contraceptive antibody in vaginal fluid, endocervical mucus, and serum by endpoint dilution.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   The study will enroll 15 couples comprised of women in monogamous heterosexual relationships with male partners.
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age 18 - 50 years, inclusive
  • General good health, by volunteer history and per investigator judgment
  • History of regular menstrual cycles of 21 - 35 days (inclusive), by volunteer report
  • History of a normal PAP smear or ASCUS with negative HPV testing within the previous 12 months
  • Willing to abstain from intercourse and use of vaginal medications, lubricants, and other products as required in the protocol
  • Willing to use non-spermicidal, lubricated condoms for any vaginal intercourse from the first day of each menstrual cycle until 72 hours before expected midcycle
  • In a mutually monogamous relationship with a male partner who:

    • Is at least 18 years old
    • Has no known risk for sexually transmitted infections (STIs)
    • Is willing and able to comply with protocol requirements including sexual activity/ abstinence and condom use requirements
    • Can engage in vaginal intercourse with the participant, with and without condoms, as specified in protocol
  • Protected from pregnancy by female surgical sterilization
  • Vaginal and cervical anatomy that, in the opinion of the investigator, lends itself to easy genital tract sample collection
  • Willing to give voluntary consent, sign an informed consent form and comply with study procedures as required by the protocol

Exclusion Criteria:

  • History of hysterectomy
  • Surgical sterility or known history of infertility in male partner
  • Sterility or known history of sperm dysfunction in male partner
  • Currently pregnant by urine pregnancy test at the enrollment visit, or within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome
  • Current use of any hormonal contraceptive or a copper or hormonal IUD, or use of Depo-Provera in the last 120 days
  • Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study
  • Significant gynecological abnormalities (including abnormal vaginal bleeding, excessive vaginal discharge, or vulvar/vaginal pain or irritation)
  • Current UTI, vaginal candidiasis, or symptomatic bacterial vaginosis
  • History of sensitivity/allergy to ZB-06 film components, for either the volunteer or her male partner
  • In the last three months, either the volunteer or her male partner diagnosed with or treated for any STI or pelvic inflammatory disease, or either partner with known risk factors for sexually transmitted infections. Note: Women with a history of genital herpes or condylomata who have been asymptomatic for at least six months may be considered for eligibility
  • Positive test for Trichomonas vaginalis, Neisseria gonorrhea, Chlamydia trachomatis, or HIV at the screening visit
  • Deep epithelial genital findings such as abrasions, ulcerations, and lacerations, or vesicles suspicious for an STI
  • Known current drug or alcohol abuse which could impact study compliance
  • Participation in any other investigational trial within the last 30 days or planned participation in any other investigational trial during the study
  • History of gynecological procedures (including genital piercing) on the external genitalia, vagina or cervix within the last 14 days
  • Abnormal finding on laboratory or physical examination or a social or medical condition in either the volunteer or her male partner which, in the opinion of the investigator, would make participation in the study unsafe or would complicate interpretation of data

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04731818

Layout table for location information
United States, Virginia
Eastern Virginia Medical School
Norfolk, Virginia, United States, 23507
Sponsors and Collaborators
ZabBio Inc.
Eastern Virginia Medical School (EVMS)
Layout table for additonal information
Responsible Party: ZabBio Inc.
ClinicalTrials.gov Identifier: NCT04731818    
Other Study ID Numbers: ZB-06-01
First Posted: February 1, 2021    Key Record Dates
Last Update Posted: June 16, 2022
Last Verified: June 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No